Surviving in biotech by own means : -if there is a will there is a way

Abstract: Sweden is the fourth largest biotechnology country in Europe and Sweden has the highest number of biotech companies per capita in the world. The sector is not yet a well established one and there haven’t been much energy put on business research, why we wanted to explore the sector more thoroughly. The purpose of our investigation was to examine different ways to survive on your own in the biotech sector. The ways should work to copy for other actors in the biotech sector. Many variables have been taken into account, such as the idea generating process, the business concept, the innovation strategy and the environmental context. The problem to be investigated was: how do you survive by own means in the biotech sector? Our main conclusion is that if there is a will there is a way to survive in the biotech sector. We have distinguished three paths, a MBO offspring, refinement of a brilliant idea and to develop a new medical application, that have been used by several of the biotech companies which we think could be suitable to others. However we are aware of the limited data in this thesis and we couldn’t state that there are other possible paths as well. Our other conclusion is that there are some variables that you need to concentrate on in the company’s different phases. In the beginning you need to focus on your idea and build up your knowledge platform. It is preferred to have another product in licensed to sell during this first period. When you have reached the main scientific goals you need to direct focus towards marketing and sales in order to create revenue for the company. You must also have a plan of who toSweden is the fourth largest biotechnology country in Europe and Sweden has the highest number of biotech companies per capita in the world. The sector is not yet a well established one and there haven’t been much energy put on business research, why we wanted to explore the sector more thoroughly. The purpose of our investigation was to examine different ways to survive on your own in the biotech sector. The ways should work to copy for other actors in the biotech sector. Many variables have been taken into account, such as the idea generating process, the business concept, the innovation strategy and the environmental context. The problem to be investigated was: how do you survive by own means in the biotech sector? Our main conclusion is that if there is a will there is a way to survive in the biotech sector. We have distinguished three paths, a MBO offspring, refinement of a brilliant idea and to develop a new medical application, that have been used by several of the biotech companies which we think could be suitable to others. However we are aware of the limited data in this thesis and we couldn’t state that there are other possible paths as well. Our other conclusion is that there are some variables that you need to concentrate on in the company’s different phases. In the beginning you need to focus on your idea and build up your knowledge platform. It is preferred to have another product in licensed to sell during this first period. When you have reached the main scientific goals you need to direct focus towards marketing and sales in order to create revenue for the company. You must also have a plan of who to Sweden is the fourth largest biotechnology country in Europe and Sweden has the highest number of biotech companies per capita in the world. The sector is not yet a well established one and there haven’t been much energy put on business research, why we wanted to explore the sector more thoroughly. The purpose of our investigation was to examine different ways to survive on your own in the biotech sector. The ways should work to copy for other actors in the biotech sector. Many variables have been taken into account, such as the idea generating process, the business concept, the innovation strategy and the environmental context. The problem to be investigated was: how do you survive by own means in the biotech sector? Our main conclusion is that if there is a will there is a way to survive in the biotech sector. We have distinguished three paths, a MBO offspring, refinement of a brilliant idea and to develop a new medical application, that have been used by several of the biotech companies which we think could be suitable to others. However we are aware of the limited data in this thesis and we couldn’t state that there are other possible paths as well. Our other conclusion is that there are some variables that you need to concentrate on in the company’s different phases. In the beginning you need to focus on your idea and build up your knowledge platform. It is preferred to have another product in licensed to sell during this first period. When you have reached the main scientific goals you need to direct focus towards marketing and sales in order to create revenue for the company. You must also have a plan of who to talk to talk to and in which order and have good contact with opinion leaders.